[Primary small cell neuroendocrine carcinoma of the larynx: a review of literature and case series].

Abstract

INTRODUCTION\n\u2002Small cell neuroendocrine carcinoma (SCNC) of the larynx is a rare tumor entity with a 5-year overall survival (OS) of only 5\u200a% after treatment with chemoradiotherapy.\n\n\nMETHODS\n\u2002A systematic review of the literature was performed for SCNC and SCNC in head and neck . Our hospital s own electronic patient file database was investigated for patients diagnosed with a SCNC over the last 12 years.\n\n\nRESULTS\n\u2002The effectiveness of chemoradiotherapy in SCNC is still unclear since randomized clinical trials are missing for the evaluation of standard of care treatment. Common therapy approaches are based on experiences with small cell lung cancer. 0.5\u200a% of all SCNC occur in the head and neck region. In the last 12 years, we diagnosed 9 patients with SCNC, two of which were located in the larynx. Exemplarily, we report the case of a 29-year-old male with the initial diagnosis of a SCNC of the larynx with concurrent lymph node metastasis. This case is particularly interesting due to the young age at disease onset and the lack of major risk factors. Treatment was modified to nivolumab due to progressive disease after treatment with chemoradiotherapy. After an OS of 22\xa0months, the patient deceased due to a tumor-associated major bleeding with airway obstruction.\n\n\nCONCLUSION\n\u2002So far there are no clinical reports evaluating the use of nivolumab in third-line-therapy of SCNC. NTRK fusion (neurotrophic tyrosine receptor kinase gene fusion) or the folate receptor expression analysis should be considered to evaluate the potential use of a tropomyosin receptor kinase inhibitor or a folate receptor targeting therapy.